LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 8 of 15: Cell count and normalized growth rate inhibition values within biological replicate 1. - Dataset (ID:20245)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Crizotinib | 0.12 | uM | LJP5 | 1 | A23 | 72 | hr | 1476 | 3191 | 3788 | 0.8423 | 0.7627 |
| SK-BR-3 | Crizotinib | 0.12 | uM | LJP5 | 2 | A23 | 72 | hr | 1476 | 3343 | 3731 | 0.8960 | 0.8423 |
| SK-BR-3 | Crizotinib | 0.12 | uM | LJP5 | 3 | A23 | 72 | hr | 1476 | 3076 | 3796 | 0.8102 | 0.7137 |
| SK-BR-3 | Crizotinib | 0.37 | uM | LJP5 | 1 | A22 | 72 | hr | 1476 | 2613 | 3788 | 0.6897 | 0.5217 |
| SK-BR-3 | Crizotinib | 0.37 | uM | LJP5 | 2 | A22 | 72 | hr | 1476 | 2875 | 3731 | 0.7705 | 0.6458 |
| SK-BR-3 | Crizotinib | 0.37 | uM | LJP5 | 3 | A22 | 72 | hr | 1476 | 2987 | 3796 | 0.7868 | 0.6771 |
| SK-BR-3 | Crizotinib | 1.11 | uM | LJP5 | 1 | A21 | 72 | hr | 1476 | 2525 | 3788 | 0.6665 | 0.4838 |
| SK-BR-3 | Crizotinib | 1.11 | uM | LJP5 | 2 | A21 | 72 | hr | 1476 | 2472 | 3731 | 0.6625 | 0.4700 |
| SK-BR-3 | Crizotinib | 1.11 | uM | LJP5 | 3 | A21 | 72 | hr | 1476 | 2390 | 3796 | 0.6295 | 0.4239 |
| SK-BR-3 | Crizotinib | 3.33 | uM | LJP5 | 1 | A20 | 72 | hr | 1476 | 1800 | 3788 | 0.4751 | 0.1568 |
| SK-BR-3 | Crizotinib | 3.33 | uM | LJP5 | 2 | A20 | 72 | hr | 1476 | 1803 | 3731 | 0.4832 | 0.1610 |
| SK-BR-3 | Crizotinib | 3.33 | uM | LJP5 | 3 | A20 | 72 | hr | 1476 | 1923 | 3796 | 0.5065 | 0.2139 |
| SK-BR-3 | Crizotinib | 10 | uM | LJP5 | 1 | A19 | 72 | hr | 1476 | 1058 | 3788 | 0.2793 | -0.2175 |
| SK-BR-3 | Crizotinib | 10 | uM | LJP5 | 2 | A19 | 72 | hr | 1476 | 1091 | 3731 | 0.2924 | -0.2026 |
| SK-BR-3 | Crizotinib | 10 | uM | LJP5 | 3 | A19 | 72 | hr | 1476 | 1135 | 3796 | 0.2990 | -0.1757 |
| SK-BR-3 | BMS345541 | 0.04 | uM | LJP6 | 1 | D06 | 72 | hr | 1476 | 3727 | 3413 | 1.0919 | 1.1509 |
| SK-BR-3 | BMS345541 | 0.04 | uM | LJP6 | 2 | D06 | 72 | hr | 1476 | 4130 | 3783 | 1.0916 | 1.1334 |
| SK-BR-3 | BMS345541 | 0.04 | uM | LJP6 | 3 | D06 | 72 | hr | 1476 | 3759 | 3734 | 1.0067 | 1.0100 |
| SK-BR-3 | BMS345541 | 0.12 | uM | LJP6 | 1 | D05 | 72 | hr | 1476 | 3881 | 3413 | 1.1370 | 1.2242 |
| SK-BR-3 | BMS345541 | 0.12 | uM | LJP6 | 2 | D05 | 72 | hr | 1476 | 3807 | 3783 | 1.0062 | 1.0091 |
| SK-BR-3 | BMS345541 | 0.12 | uM | LJP6 | 3 | D05 | 72 | hr | 1476 | 3924 | 3734 | 1.0509 | 1.0755 |
| SK-BR-3 | BMS345541 | 0.37 | uM | LJP6 | 1 | D04 | 72 | hr | 1476 | 3463 | 3413 | 1.0146 | 1.0241 |
| SK-BR-3 | BMS345541 | 0.37 | uM | LJP6 | 2 | D04 | 72 | hr | 1476 | 3960 | 3783 | 1.0466 | 1.0683 |
| SK-BR-3 | BMS345541 | 0.37 | uM | LJP6 | 3 | D04 | 72 | hr | 1476 | 3930 | 3734 | 1.0525 | 1.0779 |
| SK-BR-3 | BMS345541 | 1.11 | uM | LJP6 | 1 | D03 | 72 | hr | 1476 | 2633 | 3413 | 0.7714 | 0.6135 |